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Abstract: Follistatin has been reported as a candidate gene for polycystic ovarian syndrome 
(PCOS) based on linkage and association studies. In this study, investigation of polymorphisms in 
the FST gene was done to determine if genetic variation is associated with susceptibility to PCOS. 
The nucleotide sequence of human follistatin and the protein sequence of human   follistatin were 
retrieved from the NCBI database using Entrez. The follistatin protein of human was retrieved 
from the Swiss-Prot database. There are 344 amino acids and the molecular weight is 38,007 
Da. The ProtParam analysis shows that the isoelectric point is 5.53 and the aliphatic index is 
61.25. The hydropathicity is −0.490. The domains in FST protein are as follows: Pfam-B 5005 
domain from 1 to 92; EGF-like subdomain from 93 to 116; Kazal 1 domain, occurred in three 
places, namely, 118–164, 192–239, and 270–316. There are 31 single-  nucleotide   polymorphisms 
(SNPs) for this gene. Some are nonsynonymous, some occur in the intron region, and some in 
an untranslated region. Two nonsynonymous SNPs, namely, rs11745088 and rs1127760, were 
taken for analysis. In the SNP rs11745088, the change is E152Q. Likewise, in rs1127760, the 
change is C239S. SIFT (Sorting Intolerant from Tolerant) showed positions of amino acids and 
the single letter code of amino acids that can be tolerated or deleterious for each position. There 
were six SNP results and each result had links to it. The dbSNP id, primary database id, and the 
type of mutation whether silent and if occurring in coding region are given as phenotype altera-
tions. The FASTA format of protein was given to the nsSNP Analyzer tool, and the variation 
E152Q and C239S were given as inputs in the SNP data field. E152Q change was neutral and 
C239S causes disease. Using PANTHER for evolutionary analysis of coding SNPs, the protein 
sequence was given as input and analyzed for the E152Q and C239S SNPs for deleterious effect 
on protein function. The genetic association database results showed that FST gene SNPs are 
linked to PCOS coming under the disease class of metabolic disorders. The list of intronic and 
synonymous SNPs, with their nucleotide position, amino acid change information, and dbSNP 
link, is provided for further analysis.
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Introduction
Polycystic ovarian syndrome (PCOS) is a common endocrine disorder that is found 
in ≈4% of women of reproductive age1 and results in reduced fertility and a sevenfold 
increased risk for type 2 diabetes mellitus.2 The syndrome is characterized by hyperandro-
genism and chronic anovulation. It is also associated with polycystic ovaries,   hirsutism, 
obesity, and insulin resistance. The observation of familial aggregation of PCOS3–5 
showed that it is consistent with a genetic basis for this disorder. The mode of inheritance 
is uncertain at this point, and the role of shared environmental factors such as diet and 
lifestyle in the presentation of the disease is unknown. Loci proposed and   investigated Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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as possible PCOS genes include CYP11A, the insulin gene, 
and a region near the insulin receptor gene.6 The wide range of 
PCOS symptoms likely plays a significant role in the inability 
thus far to identify a specific gene mutation.
Single-nucleotide polymorphisms (SNPs) are DNA 
sequence variations that occur when a single nucleotide (A, 
T, C, or G) in the genome sequence is changed. Most SNPs, 
actually about two of every three SNPs, involve the replace-
ment of cytosine (C) with thymine (T). SNPs occur every 
100–300 bases along the human genome. SNPs are stable 
from an evolutionarily standpoint not changing much from 
generation to generation.
GGCTTCAGAATGGCC
GGCTTCAAAATGGCC
SNPs, which make up about 90% of all human genetic 
variation, occur every 100–300 bases along the   3-billion-base 
human genome. SNPs can occur in both coding (gene) and 
noncoding regions of the genome. Many SNPs have no effect 
on cell function, but scientists believe others could predispose 
people to disease or influence their response to a drug. SNP 
maps will help them to identify the multiple genes associated 
with such complex diseases as cancer, diabetes, vascular 
disease, and some forms of mental illness.
Several pathways have been implicated in the etiology of 
PCOS. These include the metabolic or regulatory pathways 
of steroid hormone synthesis,7,8 regulatory pathways of 
gonadotropin action,9 the insulin-signaling pathway,10–12 and 
pathways regulating body weight.13 Several genes from these 
pathways have been tested as candidate genes for PCOS.7,8,14–19 
Although mutation analysis, linkage studies, and case-control 
association studies have been carried out with these candidate 
genes, evidence that any of them play a role in PCOS has 
not been replicated widely and is still inconclusive. These 
uncertainties are common in ‘complex’ genetic diseases, 
where identifying the contributing genes is made difficult by 
likely genetic heterogeneity, environmental contributions, 
and multiple etiologies. However, the mode of inheritance of 
PCOS has not been firmly established. Although some stud-
ies support a single dominant gene with high penetrance,20–22 
others do not.23 A study was conducted by Urbanek et al24 
on a carefully chosen collection of 37 candidate genes for 
linkage and association with PCOS or hyperandrogenemia 
in data from 150 families. The authors found that strongest 
evidence for linkage was with the follistatin gene.
Strong evidence for a link between the follistatin gene and 
PCOS has been recently found in a well-designed large-scale 
study. The pathway in which follistatin gene is involved is shown 
in Figure 1 as in KEGG database: Follistatin binds to activin 
and affects its functions, for example, stimulation of follicle-
stimulating hormone (FSH) synthesis and secretion. Thus, it may 
play a role in the functional impairment of the FSH–granulosa 
cell axis in PCOS. Several genes involved in the biosynthesis 
of androgen, and action of insulin and gonadotrophin have been 
examined as candidate genes for PCOS. These genes include 
those for the cholesterol side-chain cleavage enzyme (CYP11A), 
17-hydroxylase/17,20-lyase (CYP17), insulin, insulin receptor, 
and LH. Two of them, CYP11A and the insulin gene, and variable 
number of tandem repeats, have been proposed as predisposing 
genetic factors contributing to PCOS. However, neither of them 
have been widely accepted as a major cause for this syndrome. 
Recently, in a well-designed large-scale study, Urbanek et al24 
tested for linkage and association between 37 candidate genes 
including those previously studied and PCOS. These genes 
were carefully selected from those involved in the action of 
androgen, gonadotrophin, and insulin, and also the regulation of 
obesity and energy. They found evidence for linkage only with 
the CYP11A and follistatin genes. However, only the linkage 
with follistatin gene remained significant after correction for 
multiple testing. Nevertheless, this study apparently confirmed 
previous findings which demonstrated the linkage of CYP11A 
gene with PCOS.
Follistatin is a single-chain glycosylated polypeptide that 
can bind to activin with high affinity and neutralize its biologi-
cal action of stimulating the secretion of FSH and increasing 
FSHß mRNA levels and may therefore, arrest folliculogenesis. 
Indeed, overexpression of follistatin in the transgenic mice 
resulted in the suppression of both serum concentrations of 
FSH and ovarian folliculogenesis, similar to the clinical features 
commonly found in PCOS patients. Follistatin is expressed in 
numerous tissues including the ovary, pituitary, adrenal cortex, 
and pancreas. The human cDNAs encoding follistatin have 
been cloned. There is a single follistatin gene that can gener-
ate two mature mRNA transcripts by alternative splicing, thus 
encoding proteins of 315 (FS-315) and 288 (FS-288) amino acid 
residues, respectively. The FS-288, a carboxy-truncated variant 
with increased biological potency, was found to bind strongly to 
heparin sulphate proteoglycans of the cell membrane, whereas 
FS-315 had little or no such binding affinity. Furthermore, in the 
anterior pituitary cells, FS-288 was more potent in suppressing 
FSH release. This cell-associated protein was also found to 
accelerate the uptake of activin into pituitary cells, leading to 
an increase in its degradation by lysosomal enzymes and thus 
playing a role in the activin clearance system.
In view of this, it was thought that it would be worthwhile 
to explore the role of follistatin gene and its linkage with 
PCOS. The objectives of the work are retrieval of follistatin Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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gene and protein, analysis of follistatin gene and protein, and 
SNP studies on follistatin to study SNP association with PCOS. 
Hence, in this work, SNPs in the FST gene were studied to 
determine if genetic variation is associated with susceptibility 
to PCOS or key phenotypic features of PCOS patients.
Materials and methods
The various methods, databases, tools, and software used for 
carrying out this project and their details are given below.
sequence retrieval
1.  Nucleotide – NCBI: The nucleotide sequence of human 
  follistatin was retrieved from NCBI database using 
Entrez.
2.  Protein – NCBI: The protein sequence of human   follistatin 
was retrieved from NCBI database using Entrez.
3.  Protein – Swiss-Prot: The follistatin protein of human 
was retrieved from Swiss-Prot database.
sequence analysis
1.  Protparam: The protein sequence of follistatin was given 
to Protparam search and analyzed.
2.  Pfam: The protein sequence of follistatin was given to 
Pfam search and analyzed for the protein family.
snP analysis
The follistatin gene and protein was subjected to various 
SNP analyses.
1.  NCBI – dbSNP: The SNPs of human follistatin were 
retrieved from database. The list of NCBI SNP entries 
was obtained from genecard link.
TGF-BETA SIGNALING PATHWAY
Chordin
Noggin
BMP
DAN
Growth factor
BMPRI
BMPRII
+p
+p
+p
+p
+p
+p
−p
Ras/MAPK
Smad1/5/8
Smad6/7
Smad2/3
Smad4
Smad2/3
SARA
Smurf1/2
Smad1/5/8
Smad4
IFNγ
TNFα
TGFβ
THB S1
LTBP1
Decorin
TGFβ RI
TGFβ RII
Lefty
Activin
ActivinRI
ActivinRII
NodalRII
NodalRI
Smad2/3
Smad2/3
Smad4
Smad2/3
Smad4
Smad2/3
Smad6/7
DNA
DNA
DNA
DNA
DNA DNA
Osteoblast differentiation,
neurogenesis,
ventral mesoderm specification
Transcription factors,
co-activators,
and co-repressors
Angiogenesis,
extracellular matrix,
neogenesis,
immunosuppression,
apotosis induction
Apoptosis
G1 arrest
Cell cycle
Gonadal growth,
embryo differentiation,
placenta formation, etc
Left-right axis detemination
Mesoderm and endoderm induction, etc
TAK1, MEKK1
DAXX/JNK
MAPK signaling
pathway
Ubiquitin mediated
proteolysis
+u +u
ERK
Rbx1
Cul1
Skp1
p107
E2F4/5
DPI
p300
SPI
c-Myc
p15
RhoA
PP2A
ROCK1
p70S6K
Nodal
Pitx2
FST
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2.  SIFT (Sorting Intolerant from Tolerant): The follistatin 
protein sequences were submitted as input for the SIFT 
tool.
3.  Single Amino Acid Polymorphism (SAAP): The SAAP 
is to link SNP to phenotype alterations. In this tool, the 
UniProt id P19883 was given in the search box.
4.  nsSNP Analyzer: The FASTA format of protein was given 
to the nsSNP Analyzer tool and the variation E152Q and 
C239S were given as input in the SNP data field.
5.  PANTHER – Evolutionary analysis of coding SNPs: The 
protein sequence was given as input and analyzed for the 
E152Q and C239S SNPs. Top of Form Estimates the likeli-
hood of a particular nonsynonymous (amino acid changing) 
coding SNP to cause a functional impact on the protein. It 
calculates the substitution position-specific evolutionary 
conservation (subPSEC) score based on an alignment of evo-
lutionarily related proteins, as described by Thomas et al25 
and Thomas and Kejariwal.26 Multiple sequence alignment 
(MSA) position to view the column in the MSA where the 
substitution occurs was also carried out.
6.  SNPs3D: SNPs3D is a Web site which assigns molecular 
functional effects of nonsynonymous SNPs based on 
structure and sequence analysis.
Results and discussion
sequence retrieval
1.  Nucleotide – NCBI: The nucleotide sequence of human 
follistatin was retrieved from NCBI database using 
Entrez. The accession number is BC004107 and there 
are totally 1326 base-pairs in the mRNA.
The sequence in FASTA format is given below:
. gi|33871153|gb|BC004107.2| Homo sapiens 
follistatin, mRNA (cDNA clone MGC:10663 
IMAGE:3688745), complete cds
2.  Protein – NCBI: The protein sequence of human fol-
listatin was retrieved from NCBI database using Entrez. 
The accession number is AAH04107 and there are totally 
344 amino acids in the protein.
The protein in FASTA format is given below:
. gi|13278648|gb|AAH04107.1|  follistatin 
[Homo sapiens]
3.  Protein – SWISSPROT: The follistatin protein of 
human was retrieved from SWISSPROT database and 
the accession number is P19883. There are 344 amino 
acids and the molecular weight is 38,007 Da. Out of 
the many genes follistatin was considered as a main 
candidate gene for PCOS. So, this gene was selected 
for study.
Follistatin was considered a candidate for the   following 
reasons. It is an activin-binding protein that neutralizes 
the   biological activity of activin in vivo and in vitro and is 
expressed in multiple tissues, including the ovary, pituitary, 
adrenal cortex, and pancreas. Activin, a member of the trans-
forming growth factor-ß superfamily, modulates the produc-
tion of androgens by ovarian thecal cells, the development of 
ovarian follicles, and the secretion of FSH by the pituitary and 
insulin by pancreatic ß-cells. Because follistatin inhibits the 
activity of activin, altered follistatin activity would be expected 
to affect follicular development, ovarian androgen production, 
pituitary FSH secretion, and insulin release. All these processes 
have been shown to be perturbed in PCOS.27,28
sequence analysis
1.  Protparam: The protein sequence of follistatin was given 
to Protparam search and analyzed.
2.  Pfam: The protein sequence of follistatin was given to 
Pfam search and analyzed for the protein family.
FST_HUMAN (P19883): DE follistatin precursor (FS) 
(activin-binding protein). The protparam analysis showed that 
the isoelectric point is 5.53 and the aliphatic index is 61.25. 
The hydropathicity is −0.490. The domains in FST protein 
are Pfam-B 5005 domain from 1 to 92, EGF-like subdomain 
from 93 to 116, Kazal 1 domain occurring in three places, 
namely, 118–164, 192–239, and 270–316.
Family: Kazal_1 (PF00050): Alignment also includes a 
single domain from transporters in the OATP/PGT family 
(Swiss: P46721).
Interpro entry IPR002350: This family of Kazal   inhibitors 
belongs to MEROPS inhibitor family I1, clan IA. They inhibit 
serine peptidases of the S1 family. These proteins contain 
between 1 and 7 Kazal-type inhibitor repeats. The   structure of the 
Kazal repeat includes a large quantity of extended chain, two 
short α-helices and a three-stranded antiparallel β sheet. The 
inhibitor makes 11 contacts with its enzyme substrate: unusually, 
8 of these important residues are hypervariable.
Altering the enzyme-contact residues, and especially that 
of the active site bond, affects the strength of inhibition and 
specificity of the inhibitor for particular serine proteases. The 
presence of this Pfam domain is usually indicative of serine 
protease inhibitors; however, Kazal-like domains are also 
seen in the extracellular part of agrins which are not known 
to be proteinase inhibitors.
Clan
This family is a member of clan Kazal (CL0005), which 
contains the following two members: Kazal_1 and 
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Family: EGF-like_subdom (PF09120): Members of this 
family are reminiscent of EGF-like modules, as indicated 
by an identical disulphide connectivity. This subdomain 
comprises a stretch of residues in an extended conformation 
held in place by two disulphide linkages to two β strands. 
In follistatin, it is followed by a Kazal-like sequence: both 
are required for heparan sulphate binding.
Interpro entry IPR015204: This is an EGF-like domain, 
as indicated by an identical disulphide connectivity, which 
resembles the N-terminal domain of follistatin. It comprises a 
stretch of residues in an extended conformation held in place 
by two disulphide linkages to two β strands. In follistatin, it 
is followed by a Kazal-like sequence: both are required for 
heparan sulphate binding.
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Figure 2 Thirty-one nCBi snPs in FST format.
Clan
This family is a member of clan EGF (CL0001), which con-
tains the following eight members: EGF, EGF-like_subdom, 
EGF_2, EGF_alliinase, EGF_CA, FOLN, Laminin_EGF, and 
Tme5_EGF_like.
snP analysis
The follistatin gene and protein were subjected to various 
SNP analyses.
1.  NCBI – dbSNP: The SNPs of human follistatin were 
retrieved from database. The list of NCBI SNP entries 
was obtained from genecard link. There are 31 SNPs for 
this gene and some are nonsynonymous, some occur in 
intron region, and some in untranslated region (Figure 2). 
Two nonsynonymous SNPs, namely, rs11745088 
and rs1127760, are taken for analysis. In the SNP 
rs11745088, the change is E152Q. That is E in position 
152 is changed to Q. Likewise, in rs1127760 the change 
is C239S.
Recently, in a well-designed large-scale study, 
Urbanek et al24 tested for linkage and association between 
37 candidate genes including those previously studied and 
PCOS. These genes were carefully selected from those 
involved in the action of androgen, gonadotrophin, and 
insulin, and also the regulation of obesity and energy. 
They found evidence for linkage only with the CYP11A 
and follistatin genes. However, only the linkage with 
follistatin gene remained significant after correction for 
multiple testing.
Likewise, studies of Jones et al28 in 173 Caucasian 
women suggest that polymorphism in the follistatin gene 
is associated with key androgenic phenotypes of PCOS. 
In their observation, the SNP rs3797297, located in intron 
1 of the FST gene, was significantly associated with both Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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FAI and SHBG. In both instances, post hoc analysis 
revealed that the main effect was due to subjects who were 
homozygous for rare A-allele of the polymorphism. The 
data for rs3797297 did not appear to be consistent with a 
codominant mode of expression at this locus. In subjects 
with two copies of the polymorphic allele at this locus, 
the FAI was well above the reference range, representing 
more severe hyperandrogenemia than in those women 
with a copy of the ancestral allele. Thus, a recessive effect 
appeared more likely. In the case of the SNP rs11745088, 
which was significantly associated with DHEA-S level, 
only two heterozygotes were identified for whom DHEA-S 
was available, with both these individuals having elevated 
DHEA-S. Although their study was larger than many 
molecular genetics studies of PCOS published to date, the 
power of the study remains relatively modest.
2.  SIFT: The follistatin protein sequences were   submitted 
as input for the SIFT tool. Amino acids that were not 
corresponding to its protein were indicated as ‘not 
 tolerated’ means that the change might cause some 
deleterious effects. Forty-three sequences were selected 
to be closely related to our query sequence. At position 
25R in the query sequence, 81% of the sequences have 
an amino acid appearing at this position. M, e, I, y, v, l, 
p, a, g, T, s, e, H, k, N, Q, D, R are predicted as toler-
ated and are observed in the alignment (capitalized). 
w and c are predicted to be deleterious because they 
have normalized probabilities ,0.05 and none of these 
appear in the alignment (small letters). Amino acids 
are color coded: nonpolar, uncharged polar, basic, and   
acidic.
3.  SAAP: SIFT showed positions of amino acids and the 
single letter code of amino acids that can be tolerated 
or deleterious for each position. The SAAP is to link 
SNP to phenotype alterations. In this tool, the UniProt 
id P19883 was given in the search box. The SAAP is to 
link SNP to phenotypic changes. There were six SNP 
results and each result had links to it. The dbSNP id, 
primary database id, and the type of mutation whether 
silent and if occurring in coding region are given phe-
notype alterations.
For 28 of the 37 candidate genes analyzed by 
Urbanek et al,24 there is at least one polymorphic 
marker within 1 centiMorgan (cM) of the candidate 
gene, and for the remainder, the markers are 1–4 cM 
from the candidate gene. This proximity improves the 
power of the study because recombination is likely to 
be minimal.
4.  nsSNP Analyzer: The FASTA format of protein was given 
to the nsSNP Analyzer tool and the variation E152Q and 
C239S was given as input in the SNP data field. E152Q 
change is neutral and the C239S causes disease.
5.  PANTHER – Evolutionary analysis of coding SNPs: The 
protein sequence was given as input and analyzed for the 
E152Q and C239S SNPs. The probability that a given 
variant will cause a deleterious effect on protein function 
is estimated by Pdeleterious such that a subPSEC score of −3 
corresponds to a Pdeleterious of 0.5.
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6.  SNPS3D: The disease (HGMD) and nondeleterious dataset 
were used to train and test the model. ‘0’ was used as the 
threshold of classification. A SNP with a negative support 
vector machine (SVM) score is classified as damaging 
SNP. A SNP with a positive SVM score is classified as 
neutral SNP. A higher score (±) relates a higher confidence 
in prediction. A score .0.5 is considered to be significant 
(Figure 3). The results showed that FST gene SNPs are 
linked to PCOS coming under the disease class of meta-
bolic disorders.
Activin, a member of the transforming growth factor-b 
superfamily, and follistatin are expressed in several tissues, 
such as ovary, pituitary, adrenal cortex, and pancreas. This 
similar pattern of tissue distribution suggests that follistatin 
is likely to be an auto-/paracrine regulator of the hormonal 
effects of activin within the tissues. In particular, activin 
promotes ovarian follicular development, enhances LH 
binding sites and progesterone production, playing a role in 
preventing premature luteinization of the ovarian follicles, 
inhibits thecal cell androgen production, and increases 
pituitary FSH secretion and insulin secretion by pancreatic 
b-cells. An increase in circulating level or biological activity 
of follistatin may, therefore, cause follicular development 
to be arrested, the process of follicular luteinization or 
atresia to be favored, ovarian androgen production to be 
increased, FSH circulating levels to be reduced, and insulin 
release to be impaired. These effects are all characteristic 
features of PCOS.29
Follistatin is a single-chain glycoprotein that primarily 
acts to regulate the activity of activin, which is responsible 
for ovarian follicular development, inhibition of theca 
cell androgen production and increases in both pituitary 
FSH secretion and pancreatic insulin secretion.30 Primar-
ily synthesized in the granulosa cells of the ovarian antral 
follicle, follistatin mRNA increases within the dominant 
follicle during development and declines during the atretic 
process.31 Follistatin acts to suppress aromatase activity in 
the granulosa cell and also LH-stimulated progesterone 
release from thecal cells.32 The overexpression of follistatin 
in mice has been shown to result in arrested ovarian fol-
licular development and reduced levels of FSH, both key 
phenotypes of PCOS.27
The list of intronic and synonymous SNPs, with their 
nucleotide position, amino acid change information, and 
dbSNP link, is provided for further analysis.   Researchers 
were unable to detect any mutation of the activating or 
inhibiting type in the entire coding region of follistatin 
gene in 64 patients with PCOS. Therefore, mutations in the 
  coding regions of the follistatin gene may not be a common 
cause of PCOS in the population studied. However, it is 
possible that mutations may reside in the regulatory region 
of the gene, which should be screened once its sequence 
is known. Furthermore, it would be of great interest to 
  investigate the presence of mutations in PCOS patients in 
other ethnic populations, especially of European origin, as it 
was in this population that the linkage between the follistatin 
gene and PCOS was established.33
Strong evidence for a link between the follistatin gene 
and PCOS has been recently found in a well-designed large-
scale study. Odunsi and Kidd34 are of the opinion that over-
expression of follistatin will be expected to lead to increased 
ovarian androgen production and reduction in circulating FSH 
levels, which are features of PCOS. The genetic association 
database results show that FST gene SNPs are linked to PCOS 
coming under the disease class of metabolic disorders. The 
list of intronic and synonymous SNPs, with their nucleotide 
position, amino acid change information, and dbSNP link, is 
provided for further analysis.
The authors thus conclude that there is an association 
between FST gene SNPs and polycystic ovarian syndrome.
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